Eli Lilly and Co’s Options: A Look at What the Big Money is Thinking
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly and…
Alibaba Gr Hldgs Options Trading: A Deep Dive into Market Sentiment
Financial giants have made a conspicuous bearish move on Alibaba Gr Hldgs. Our analysis of options history for…
Analyst Scoreboard: 10 Ratings For Thermo Fisher Scientific
10 analysts have expressed a variety of opinions on Thermo Fisher Scientific (NYSE:TMO) over the past quarter, offering…
Navigating 4 Analyst Ratings For Hello Gr
Across the recent three months, 4 analysts have shared their insights on Hello Gr (NASDAQ:MOMO), expressing a variety…
Analyst Scoreboard: 4 Ratings For Akoya Biosciences
Ratings for Akoya Biosciences (NASDAQ:AKYA) were provided by 4 analysts in the past three months, showcasing a mix…
What 9 Analyst Ratings Have To Say About Okta
Okta (NASDAQ:OKTA) has been analyzed by 9 analysts in the last three months, revealing a diverse range of…
Qualcomm Promises New Chips Will Power Unprecedented PC Battery Life
Qualcomm is supplying the semiconductors for Microsoft Corp's latest Copilot+ PCs, which incorporate advanced AI features.
This MongoDB Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Nasdaq Surges 150 Points; US Manufacturing PMI Rises In May
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. The…
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.